Cytokinetics (CYTK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2026 | 03-2026 | 12-2025 | 09-2025 | 06-2025 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 255,271 | 129,843 | 122,518 | 225,467 | 74,940 |
| Marketable Securities | 910,415 | 688,707 | 759,703 | 737,068 | 783,195 |
| Receivables | 24,432 | 6,827 | 17,764 | 1,808 | 8,410 |
| Inventories | 380 | 154 | N/A | N/A | N/A |
| TOTAL | $1,208,487 | $839,465 | $916,975 | $977,349 | $886,542 |
| Non-Current Assets | |||||
| PPE Net | 78,916 | 82,438 | 79,194 | 76,001 | 70,219 |
| Investments And Advances | 538,317 | 254,719 | 335,048 | 288,817 | 178,201 |
| Other Non-Current Assets | 98,831 | 96,856 | 93,320 | 94,390 | 90,673 |
| TOTAL | $716,064 | $434,013 | $507,562 | $459,208 | $339,093 |
| Total Assets | $1,924,551 | $1,273,478 | $1,424,537 | $1,436,557 | $1,225,635 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 27,358 | 44,808 | 41,181 | 37,927 | 14,400 |
| Accounts payable and accrued liabilities | 97,372 | 24,709 | 105,615 | 22,084 | 16,228 |
| Accrued Expenses | N/A | 68,863 | N/A | 61,633 | 52,315 |
| Other current liabilities | 34,004 | 38,192 | 34,933 | 18,888 | 27,192 |
| TOTAL | $181,429 | $199,185 | $202,452 | $142,144 | $131,064 |
| Non-Current Liabilities | |||||
| Long Term Debt | 248,202 | 247,209 | 246,384 | 158,747 | 159,058 |
| Deferred Revenues | 1,653 | 1,653 | 1,612 | 1,612 | 1,344 |
| Other Non-Current Liabilities | 1,668,407 | 1,653,652 | 1,635,326 | 1,656,789 | 1,304,233 |
| TOTAL | $1,916,609 | $1,900,861 | $1,881,710 | $1,815,536 | $1,463,291 |
| Total Liabilities | $2,098,038 | $2,100,046 | $2,084,162 | $1,957,680 | $1,594,355 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 139,023 | 124,433 | 123,163 | 122,265 | 119,657 |
| Common Shares | 138 | 124 | 123 | 122 | 119 |
| Retained earnings | -3,891,512 | -3,692,750 | -3,486,719 | -3,303,688 | -2,997,510 |
| Other shareholders' equity | -3,826 | -1,612 | 630 | 34 | -158 |
| TOTAL | $-173,487 | $-826,568 | $-659,625 | $-521,123 | $-368,720 |
| Total Liabilities And Equity | $1,924,551 | $1,273,478 | $1,424,537 | $1,436,557 | $1,225,635 |